Idiopathic Pulmonary Fibrosis: New Insights on Functional Characteristics at Diagnosis
Overview
Affiliations
Background: The lung function of patients with idiopathic pulmonary fibrosis (IPF) has not been characterized in detail. objective: To characterize the heterogeneous physiological abnormalities that exist in patients with IPF during their initial clinical evaluation.
Methods: Lung function tests from 93 patients, performed within six months of the initial diagnosis of IPF, were obtained from a referral pulmonary function laboratory at a tertiary care hospital in Canada. A restrictive pattern was defined as total lung capacity (TLC) <95th percentile of predicted value. Patients with obstructive lung disease, lung cancer, emphysema and other restrictive lung diseases were excluded.
Results: On diagnosis, 73% of patients with IPF had a restrictive pattern, with a mean TLC of 72% of predicted. Mean forced vital capacity (FVC) was 71% and 44% of patients had an FVC <95th percentile. Mean diffusing capacity for carbon monoxide (DLCO) was 60% and DLCO⁄alveolar volume (VA) 92% of predicted. Increased severity of restriction - based on TLC - was associated with lower DLCO (74% of predicted in mild restriction and 39% of predicted in severe restriction) and higher forced expiratory volume in 1 s (FEV1)⁄FVC ratio (82% of predicted in mild restriction and 90% of predicted in severe restriction) but not with age (76 years in mild restriction and 69 years in severe restriction). Regardless of severity of restriction, the average DLCO⁄VA (≥86% of predicted) remained within normal limits.
Conclusions: One in four patients with IPF had normal TLC and more than one-half had a normal FVC during initial evaluation. As the severity of the restriction increased, FEV1⁄FVC increased, DLCO decreased but DLCO⁄VA remained normal.
Imaging of Pulmonary Sarcoidosis-A Review.
Bailey G, Wells A, Desai S J Clin Med. 2024; 13(3).
PMID: 38337517 PMC: 10856519. DOI: 10.3390/jcm13030822.
Murgo A, Bignami F, Federico G, Villetti G, Civelli M, Sala A Front Pharmacol. 2023; 14:1303646.
PMID: 38099140 PMC: 10719847. DOI: 10.3389/fphar.2023.1303646.
Precision medicine advances in idiopathic pulmonary fibrosis.
Karampitsakos T, Juan-Guardela B, Tzouvelekis A, Herazo-Maya J EBioMedicine. 2023; 95:104766.
PMID: 37625268 PMC: 10469771. DOI: 10.1016/j.ebiom.2023.104766.
Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks.
Patrucco F, Solidoro P, Gavelli F, Apostolo D, Bellan M Microorganisms. 2023; 11(4).
PMID: 37110318 PMC: 10146995. DOI: 10.3390/microorganisms11040895.
Fibrotic-like abnormalities notably prevalent one year after hospitalization with COVID-19.
van Raaij B, Stoger J, Hinnen C, Penfornis K, de Jong C, Klok F Respir Med Res. 2022; 82:100973.
PMID: 36403358 PMC: 9670737. DOI: 10.1016/j.resmer.2022.100973.